Solaraze® is a topical gel product for actinic keratosis that was developed by Skyepharma using its proprietary technologies. The product is marketed in the US by Sandoz and in Europe and certain other territories by Almirall. It is available for licensing in a limited number of other countries.

Sandoz Amirall


Partners: Fougera Pharmaceuticals Inc (Sandoz) and Almirall SA

Technology challenge

Diclofenac is a non-steroidal anti-inflammatory drug that is used for the symptomatic treatment of pain and inflammation. However, it does not readily cross the skin. The challenge was to develop an aesthetically acceptable formulation of diclofenac that would create a depot in the skin in sufficient quantities to exert a therapeutic effect for the treatment of actinic keratosis.

Skyepharma’s solution

We applied our proprietary hyaluronic acid technology to maximize the concentration of diclofenac in the upper layers of the skin in a cosmetically acceptable gel formulation.

Outcome

The product has been approved in more than 15 countries where it is sold by our licensees Fougera Pharmaceuticals Inc (Sandoz) and Almirall SA, and offers patients an alternative to conventional therapies that can be painful or disfiguring.

It is available for licensing in a limited number of other countries.

Please contact us to discuss availability.

Skyepharma has out-licensed the remainder of its topical technologies to focus on oral and inhalation technologies.

Disclaimer Masterpage